Can I read Real-World Experience With Tofacitinib Dose De-Escalation in Patients With Moderate and Severe Ulcerative Colitis on EtoBox?

Real-World Experience With Tofacitinib Dose De-Escalation in Patients With Moderate and Severe Ulcerative Colitis by Amy Yu; Nghiem B. Ha; Bingyan Shi; Yao-Wen Cheng; Uma Mahadevan; Kendall R. Beck is a Medicine article available to read on EtoBox.

What is Real-World Experience With Tofacitinib Dose De-Escalation in Patients With Moderate and Severe Ulcerative Colitis about?

## BACKGROUND & AIMS: Tofacitinib is associated with sustained steroid-free remission in patients with ulcerative colitis (UC), with the lowest effective dose recommended for maintenance therapy. However, there are limited real-world data to guide decisions on the optimal maintenance regimen. We aimed to evaluate predictors and outcomes of disease activity after tofacitinib dose de-escalation in this population. ## METHODS: Included were adults with moderate-severe UC treated with tofacitinib between June 2012 and January 2022. The primary outcome was evidence of UC disease activity-related events: hospitalization/surgery, corticosteroid initiation, tofacitinib dose increase, or therapy switch. ## RESULTS: Among 162 patients, 52% continued 10 mg twice daily while 48% underwent dose deescalation to 5 mg twice daily. Cumulative incidence rates of UC events at 12 months were similar in patients with and without dose de-escalation (56% vs 58%; P [ .81). In univariable Cox regression among patients with dose de-escalation, an induction course with 10 mg twice daily for more than 16 weeks was protective of UC events (hazard ratio [HR], 0.37; 95% CI, 0.16-0.85) while ongoing severe diseas

Who reads Real-World Experience With Tofacitinib Dose De-Escalation in Patients With Moderate and Severe Ulcerative Colitis?

Author

Amy Yu; Nghiem B. Ha; Bingyan Shi; Yao-Wen Cheng; Uma Mahadevan; Kendall R. Beck

Publisher

Elsevier BV

Published

2023

Language

EN

Field

Medicine (Health Sciences)